Internal Dosimetry in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-[DOTA0-Tyr3 octerotate: A Single-Center Experience Article Swipe
Elahe Mahmoudi
,
Mahasti Amoui
,
Mohammad Reza Deevband
,
Elahe Pirayesh
,
Mojtaba Asgari
,
Mahdi Ghorbani
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.18502/fbt.v12i1.17731
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.18502/fbt.v12i1.17731
Purpose: Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE (177 Lu DOTA-TATE therapy is a form of PRRT which targets Somatostatin Receptors (SSR). It is a form of targeted drug delivery, which is applicable to treat neuroendocrine tumors. PRRT applications are continuously expanding in most departments of nuclear medicine in Iran, but the best of all, no one has studied the mean doses of organs of the patients. This research aims to specify the absorbed dose to patients for the treatment of neuroendocrine tumors using imaging with 177Lu-[DOTA0-Tyr3] octerotate. Materials and Methods: Whole body planar scintigraphy images were collected for 10 patients, which are used as the basis for the personalized patient dosimetry calculations. The patients had a mean age of 53.5 ± 12 years (ranging from 36 to 70 years) and imaging data were collected at roughly 0 to 2 hours, 4 to 6 hours, 18 to 24 hours, and 36 to 48 hours after the injection of 6401± 628.4 MBq (range of 5500 MBq-7400 MBq) of 177Lu-[DOTA0-Tyr3] octerotate. Models of time-activity were established for different organs. Finally, using absorbed dose formulation and IDIAC-Dosage software, the mean absorbed dose in the organs was determined. Results: Mean calculated dose in the kidney and liver were obtained as 0.30-0.82 mGy/ MBq, and 1.05-2.11 mGy/MBq, respectively. Conclusion: Based on the results, PRRT therapy is a safe method for the treatment of castration-resistant neuroendocrine cancer patients in terms of patient dose. Large inter-individual differences in organ dose were discovered, highlighting the importance of patient-specific dosimetry and treatment planning in the treatment with 177Lu-DOTATATE.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.18502/fbt.v12i1.17731
- OA Status
- diamond
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4407051260
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4407051260Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.18502/fbt.v12i1.17731Digital Object Identifier
- Title
-
Internal Dosimetry in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-[DOTA0-Tyr3 octerotate: A Single-Center ExperienceWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-01-31Full publication date if available
- Authors
-
Elahe Mahmoudi, Mahasti Amoui, Mohammad Reza Deevband, Elahe Pirayesh, Mojtaba Asgari, Mahdi GhorbaniList of authors in order
- Landing page
-
https://doi.org/10.18502/fbt.v12i1.17731Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
diamondOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.18502/fbt.v12i1.17731Direct OA link when available
- Concepts
-
Radionuclide therapy, Medicine, Nuclear medicine, Neuroendocrine tumors, Dosimetry, Peptide receptor, Absorbed dose, Scintigraphy, Internal medicine, ReceptorTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4407051260 |
|---|---|
| doi | https://doi.org/10.18502/fbt.v12i1.17731 |
| ids.doi | https://doi.org/10.18502/fbt.v12i1.17731 |
| ids.openalex | https://openalex.org/W4407051260 |
| fwci | 0.0 |
| type | article |
| title | Internal Dosimetry in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-[DOTA0-Tyr3 octerotate: A Single-Center Experience |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10754 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9991999864578247 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2713 |
| topics[0].subfield.display_name | Epidemiology |
| topics[0].display_name | Neuroendocrine Tumor Research Advances |
| topics[1].id | https://openalex.org/T11395 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9987999796867371 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2741 |
| topics[1].subfield.display_name | Radiology, Nuclear Medicine and Imaging |
| topics[1].display_name | Radiopharmaceutical Chemistry and Applications |
| topics[2].id | https://openalex.org/T10522 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9952999949455261 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2741 |
| topics[2].subfield.display_name | Radiology, Nuclear Medicine and Imaging |
| topics[2].display_name | Medical Imaging Techniques and Applications |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2993559085 |
| concepts[0].level | 2 |
| concepts[0].score | 0.9546058177947998 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q2126444 |
| concepts[0].display_name | Radionuclide therapy |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.7630181312561035 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2989005 |
| concepts[2].level | 1 |
| concepts[2].score | 0.6819807887077332 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q214963 |
| concepts[2].display_name | Nuclear medicine |
| concepts[3].id | https://openalex.org/C2779066768 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6773650050163269 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1981276 |
| concepts[3].display_name | Neuroendocrine tumors |
| concepts[4].id | https://openalex.org/C75088862 |
| concepts[4].level | 2 |
| concepts[4].score | 0.6668625473976135 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q2291081 |
| concepts[4].display_name | Dosimetry |
| concepts[5].id | https://openalex.org/C3017732841 |
| concepts[5].level | 3 |
| concepts[5].score | 0.6518941521644592 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q25098597 |
| concepts[5].display_name | Peptide receptor |
| concepts[6].id | https://openalex.org/C151337348 |
| concepts[6].level | 3 |
| concepts[6].score | 0.5949783325195312 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q215313 |
| concepts[6].display_name | Absorbed dose |
| concepts[7].id | https://openalex.org/C2779902710 |
| concepts[7].level | 2 |
| concepts[7].score | 0.47216078639030457 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1130465 |
| concepts[7].display_name | Scintigraphy |
| concepts[8].id | https://openalex.org/C126322002 |
| concepts[8].level | 1 |
| concepts[8].score | 0.3420751392841339 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[8].display_name | Internal medicine |
| concepts[9].id | https://openalex.org/C170493617 |
| concepts[9].level | 2 |
| concepts[9].score | 0.14036154747009277 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q208467 |
| concepts[9].display_name | Receptor |
| keywords[0].id | https://openalex.org/keywords/radionuclide-therapy |
| keywords[0].score | 0.9546058177947998 |
| keywords[0].display_name | Radionuclide therapy |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.7630181312561035 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/nuclear-medicine |
| keywords[2].score | 0.6819807887077332 |
| keywords[2].display_name | Nuclear medicine |
| keywords[3].id | https://openalex.org/keywords/neuroendocrine-tumors |
| keywords[3].score | 0.6773650050163269 |
| keywords[3].display_name | Neuroendocrine tumors |
| keywords[4].id | https://openalex.org/keywords/dosimetry |
| keywords[4].score | 0.6668625473976135 |
| keywords[4].display_name | Dosimetry |
| keywords[5].id | https://openalex.org/keywords/peptide-receptor |
| keywords[5].score | 0.6518941521644592 |
| keywords[5].display_name | Peptide receptor |
| keywords[6].id | https://openalex.org/keywords/absorbed-dose |
| keywords[6].score | 0.5949783325195312 |
| keywords[6].display_name | Absorbed dose |
| keywords[7].id | https://openalex.org/keywords/scintigraphy |
| keywords[7].score | 0.47216078639030457 |
| keywords[7].display_name | Scintigraphy |
| keywords[8].id | https://openalex.org/keywords/internal-medicine |
| keywords[8].score | 0.3420751392841339 |
| keywords[8].display_name | Internal medicine |
| keywords[9].id | https://openalex.org/keywords/receptor |
| keywords[9].score | 0.14036154747009277 |
| keywords[9].display_name | Receptor |
| language | en |
| locations[0].id | doi:10.18502/fbt.v12i1.17731 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210201966 |
| locations[0].source.issn | 2345-5829, 2345-5837 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2345-5829 |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Frontiers in biomedical technologies |
| locations[0].source.host_organization | https://openalex.org/P4310319396 |
| locations[0].source.host_organization_name | Knowledge E |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310319396 |
| locations[0].license | cc-by-nc |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Frontiers in Biomedical Technologies |
| locations[0].landing_page_url | https://doi.org/10.18502/fbt.v12i1.17731 |
| locations[1].id | pmh:oai:doaj.org/article:4d1fc4139f834dd8a3bd87784afed21a |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306401280 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[1].source.host_organization | |
| locations[1].source.host_organization_name | |
| locations[1].source.host_organization_lineage | |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | article |
| locations[1].license_id | |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Frontiers in Biomedical Technologies, Vol 12, Iss 1 (2025) |
| locations[1].landing_page_url | https://doaj.org/article/4d1fc4139f834dd8a3bd87784afed21a |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5102806147 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-3184-4284 |
| authorships[0].author.display_name | Elahe Mahmoudi |
| authorships[0].countries | IR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I58048189 |
| authorships[0].affiliations[0].raw_affiliation_string | Biomedical Engineering and Medical Physics Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| authorships[0].institutions[0].id | https://openalex.org/I58048189 |
| authorships[0].institutions[0].ror | https://ror.org/034m2b326 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I58048189 |
| authorships[0].institutions[0].country_code | IR |
| authorships[0].institutions[0].display_name | Shahid Beheshti University of Medical Sciences |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Elahe Mahmoudi |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Biomedical Engineering and Medical Physics Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| authorships[1].author.id | https://openalex.org/A5064189017 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Mahasti Amoui |
| authorships[1].countries | IR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I58048189 |
| authorships[1].affiliations[0].raw_affiliation_string | Nuclear Medicine Department, Shohada-e Tajrish Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| authorships[1].institutions[0].id | https://openalex.org/I58048189 |
| authorships[1].institutions[0].ror | https://ror.org/034m2b326 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I58048189 |
| authorships[1].institutions[0].country_code | IR |
| authorships[1].institutions[0].display_name | Shahid Beheshti University of Medical Sciences |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Mahasti Amoui |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Nuclear Medicine Department, Shohada-e Tajrish Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| authorships[2].author.id | https://openalex.org/A5051631190 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-4795-1853 |
| authorships[2].author.display_name | Mohammad Reza Deevband |
| authorships[2].countries | IR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I58048189 |
| authorships[2].affiliations[0].raw_affiliation_string | Biomedical Engineering and Medical Physics Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| authorships[2].institutions[0].id | https://openalex.org/I58048189 |
| authorships[2].institutions[0].ror | https://ror.org/034m2b326 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I58048189 |
| authorships[2].institutions[0].country_code | IR |
| authorships[2].institutions[0].display_name | Shahid Beheshti University of Medical Sciences |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Mohammad Reza Deevband |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Biomedical Engineering and Medical Physics Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| authorships[3].author.id | https://openalex.org/A5067763296 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-1354-6312 |
| authorships[3].author.display_name | Elahe Pirayesh |
| authorships[3].countries | IR |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I58048189 |
| authorships[3].affiliations[0].raw_affiliation_string | Nuclear Medicine Department, Shohada-e Tajrish Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| authorships[3].institutions[0].id | https://openalex.org/I58048189 |
| authorships[3].institutions[0].ror | https://ror.org/034m2b326 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I58048189 |
| authorships[3].institutions[0].country_code | IR |
| authorships[3].institutions[0].display_name | Shahid Beheshti University of Medical Sciences |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Elahe Pirayesh |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Nuclear Medicine Department, Shohada-e Tajrish Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| authorships[4].author.id | https://openalex.org/A5036001077 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-6625-5792 |
| authorships[4].author.display_name | Mojtaba Asgari |
| authorships[4].countries | IR |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I58048189 |
| authorships[4].affiliations[0].raw_affiliation_string | Biomedical Engineering and Medical Physics Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| authorships[4].institutions[0].id | https://openalex.org/I58048189 |
| authorships[4].institutions[0].ror | https://ror.org/034m2b326 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I58048189 |
| authorships[4].institutions[0].country_code | IR |
| authorships[4].institutions[0].display_name | Shahid Beheshti University of Medical Sciences |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Mohammad Reza Asgari |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Biomedical Engineering and Medical Physics Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| authorships[5].author.id | https://openalex.org/A5085566189 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-5518-8870 |
| authorships[5].author.display_name | Mahdi Ghorbani |
| authorships[5].countries | IR |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I58048189 |
| authorships[5].affiliations[0].raw_affiliation_string | Biomedical Engineering and Medical Physics Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| authorships[5].institutions[0].id | https://openalex.org/I58048189 |
| authorships[5].institutions[0].ror | https://ror.org/034m2b326 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I58048189 |
| authorships[5].institutions[0].country_code | IR |
| authorships[5].institutions[0].display_name | Shahid Beheshti University of Medical Sciences |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Mahdi Ghorbani |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Biomedical Engineering and Medical Physics Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.18502/fbt.v12i1.17731 |
| open_access.oa_status | diamond |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Internal Dosimetry in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-[DOTA0-Tyr3 octerotate: A Single-Center Experience |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10754 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9991999864578247 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2713 |
| primary_topic.subfield.display_name | Epidemiology |
| primary_topic.display_name | Neuroendocrine Tumor Research Advances |
| related_works | https://openalex.org/W2414683342, https://openalex.org/W4388673759, https://openalex.org/W3020695212, https://openalex.org/W3138693898, https://openalex.org/W4310040010, https://openalex.org/W2795287337, https://openalex.org/W2898533025, https://openalex.org/W2582830599, https://openalex.org/W4404548396, https://openalex.org/W2895631977 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.18502/fbt.v12i1.17731 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210201966 |
| best_oa_location.source.issn | 2345-5829, 2345-5837 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2345-5829 |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Frontiers in biomedical technologies |
| best_oa_location.source.host_organization | https://openalex.org/P4310319396 |
| best_oa_location.source.host_organization_name | Knowledge E |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310319396 |
| best_oa_location.license | cc-by-nc |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Frontiers in Biomedical Technologies |
| best_oa_location.landing_page_url | https://doi.org/10.18502/fbt.v12i1.17731 |
| primary_location.id | doi:10.18502/fbt.v12i1.17731 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210201966 |
| primary_location.source.issn | 2345-5829, 2345-5837 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2345-5829 |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Frontiers in biomedical technologies |
| primary_location.source.host_organization | https://openalex.org/P4310319396 |
| primary_location.source.host_organization_name | Knowledge E |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310319396 |
| primary_location.license | cc-by-nc |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Frontiers in Biomedical Technologies |
| primary_location.landing_page_url | https://doi.org/10.18502/fbt.v12i1.17731 |
| publication_date | 2025-01-31 |
| publication_year | 2025 |
| referenced_works_count | 0 |
| abstract_inverted_index.0 | 137 |
| abstract_inverted_index.2 | 139 |
| abstract_inverted_index.4 | 141 |
| abstract_inverted_index.6 | 143 |
| abstract_inverted_index.a | 13, 24, 116, 221 |
| abstract_inverted_index.10 | 99 |
| abstract_inverted_index.12 | 122 |
| abstract_inverted_index.18 | 145 |
| abstract_inverted_index.24 | 147 |
| abstract_inverted_index.36 | 126, 150 |
| abstract_inverted_index.48 | 152 |
| abstract_inverted_index.70 | 128 |
| abstract_inverted_index.It | 22 |
| abstract_inverted_index.Lu | 9 |
| abstract_inverted_index.as | 104, 205 |
| abstract_inverted_index.at | 135 |
| abstract_inverted_index.in | 42, 48, 189, 198, 232, 240, 254 |
| abstract_inverted_index.is | 12, 23, 31, 220 |
| abstract_inverted_index.no | 55 |
| abstract_inverted_index.of | 15, 26, 45, 53, 62, 64, 80, 119, 157, 162, 166, 170, 227, 234, 248 |
| abstract_inverted_index.on | 215 |
| abstract_inverted_index.to | 33, 70, 75, 127, 138, 142, 146, 151 |
| abstract_inverted_index.± | 121 |
| abstract_inverted_index.MBq | 160 |
| abstract_inverted_index.The | 113 |
| abstract_inverted_index.age | 118 |
| abstract_inverted_index.and | 89, 130, 149, 182, 201, 209, 251 |
| abstract_inverted_index.are | 39, 102 |
| abstract_inverted_index.but | 50 |
| abstract_inverted_index.for | 77, 98, 107, 174, 224 |
| abstract_inverted_index.had | 115 |
| abstract_inverted_index.has | 57 |
| abstract_inverted_index.one | 56 |
| abstract_inverted_index.the | 51, 59, 65, 72, 78, 105, 108, 155, 185, 190, 199, 216, 225, 246, 255 |
| abstract_inverted_index.was | 192 |
| abstract_inverted_index.(177 | 8 |
| abstract_inverted_index.53.5 | 120 |
| abstract_inverted_index.5500 | 163 |
| abstract_inverted_index.MBq) | 165 |
| abstract_inverted_index.MBq, | 208 |
| abstract_inverted_index.Mean | 195 |
| abstract_inverted_index.PRRT | 16, 37, 218 |
| abstract_inverted_index.This | 67 |
| abstract_inverted_index.aims | 69 |
| abstract_inverted_index.all, | 54 |
| abstract_inverted_index.best | 52 |
| abstract_inverted_index.body | 92 |
| abstract_inverted_index.data | 132 |
| abstract_inverted_index.dose | 74, 180, 188, 197, 242 |
| abstract_inverted_index.drug | 28 |
| abstract_inverted_index.form | 14, 25 |
| abstract_inverted_index.from | 125 |
| abstract_inverted_index.mGy/ | 207 |
| abstract_inverted_index.mean | 60, 117, 186 |
| abstract_inverted_index.most | 43 |
| abstract_inverted_index.safe | 222 |
| abstract_inverted_index.used | 103 |
| abstract_inverted_index.were | 96, 133, 172, 203, 243 |
| abstract_inverted_index.with | 6, 85, 257 |
| abstract_inverted_index.628.4 | 159 |
| abstract_inverted_index.Based | 214 |
| abstract_inverted_index.Iran, | 49 |
| abstract_inverted_index.Large | 237 |
| abstract_inverted_index.Whole | 91 |
| abstract_inverted_index.after | 154 |
| abstract_inverted_index.basis | 106 |
| abstract_inverted_index.dose. | 236 |
| abstract_inverted_index.doses | 61 |
| abstract_inverted_index.hours | 153 |
| abstract_inverted_index.liver | 202 |
| abstract_inverted_index.organ | 241 |
| abstract_inverted_index.terms | 233 |
| abstract_inverted_index.treat | 34 |
| abstract_inverted_index.using | 83, 178 |
| abstract_inverted_index.which | 17, 30, 101 |
| abstract_inverted_index.years | 123 |
| abstract_inverted_index.(PRRT) | 5 |
| abstract_inverted_index.(SSR). | 21 |
| abstract_inverted_index.(range | 161 |
| abstract_inverted_index.6401± | 158 |
| abstract_inverted_index.Models | 169 |
| abstract_inverted_index.cancer | 230 |
| abstract_inverted_index.hours, | 140, 144, 148 |
| abstract_inverted_index.images | 95 |
| abstract_inverted_index.kidney | 200 |
| abstract_inverted_index.method | 223 |
| abstract_inverted_index.organs | 63, 191 |
| abstract_inverted_index.planar | 93 |
| abstract_inverted_index.tumors | 82 |
| abstract_inverted_index.years) | 129 |
| abstract_inverted_index.Peptide | 1 |
| abstract_inverted_index.Therapy | 4 |
| abstract_inverted_index.imaging | 84, 131 |
| abstract_inverted_index.nuclear | 46 |
| abstract_inverted_index.organs. | 176 |
| abstract_inverted_index.patient | 110, 235 |
| abstract_inverted_index.roughly | 136 |
| abstract_inverted_index.specify | 71 |
| abstract_inverted_index.studied | 58 |
| abstract_inverted_index.targets | 18 |
| abstract_inverted_index.therapy | 11, 219 |
| abstract_inverted_index.tumors. | 36 |
| abstract_inverted_index.(ranging | 124 |
| abstract_inverted_index.Finally, | 177 |
| abstract_inverted_index.MBq-7400 | 164 |
| abstract_inverted_index.Methods: | 90 |
| abstract_inverted_index.Purpose: | 0 |
| abstract_inverted_index.Receptor | 2 |
| abstract_inverted_index.Results: | 194 |
| abstract_inverted_index.absorbed | 73, 179, 187 |
| abstract_inverted_index.mGy/MBq, | 211 |
| abstract_inverted_index.medicine | 47 |
| abstract_inverted_index.obtained | 204 |
| abstract_inverted_index.patients | 76, 114, 231 |
| abstract_inverted_index.planning | 253 |
| abstract_inverted_index.research | 68 |
| abstract_inverted_index.results, | 217 |
| abstract_inverted_index.targeted | 27 |
| abstract_inverted_index.0.30-0.82 | 206 |
| abstract_inverted_index.1.05-2.11 | 210 |
| abstract_inverted_index.DOTA-TATE | 10 |
| abstract_inverted_index.Materials | 88 |
| abstract_inverted_index.Receptors | 20 |
| abstract_inverted_index.collected | 97, 134 |
| abstract_inverted_index.delivery, | 29 |
| abstract_inverted_index.different | 175 |
| abstract_inverted_index.dosimetry | 111, 250 |
| abstract_inverted_index.expanding | 41 |
| abstract_inverted_index.injection | 156 |
| abstract_inverted_index.patients, | 100 |
| abstract_inverted_index.patients. | 66 |
| abstract_inverted_index.software, | 184 |
| abstract_inverted_index.treatment | 79, 226, 252, 256 |
| abstract_inverted_index.applicable | 32 |
| abstract_inverted_index.calculated | 196 |
| abstract_inverted_index.importance | 247 |
| abstract_inverted_index.Conclusion: | 213 |
| abstract_inverted_index.departments | 44 |
| abstract_inverted_index.determined. | 193 |
| abstract_inverted_index.differences | 239 |
| abstract_inverted_index.discovered, | 244 |
| abstract_inverted_index.established | 173 |
| abstract_inverted_index.formulation | 181 |
| abstract_inverted_index.octerotate. | 87, 168 |
| abstract_inverted_index.IDIAC-Dosage | 183 |
| abstract_inverted_index.Radionuclide | 3 |
| abstract_inverted_index.Somatostatin | 19 |
| abstract_inverted_index.applications | 38 |
| abstract_inverted_index.continuously | 40 |
| abstract_inverted_index.highlighting | 245 |
| abstract_inverted_index.personalized | 109 |
| abstract_inverted_index.scintigraphy | 94 |
| abstract_inverted_index.calculations. | 112 |
| abstract_inverted_index.respectively. | 212 |
| abstract_inverted_index.time-activity | 171 |
| abstract_inverted_index.177Lu-DOTATATE | 7 |
| abstract_inverted_index.neuroendocrine | 35, 81, 229 |
| abstract_inverted_index.177Lu-DOTATATE. | 258 |
| abstract_inverted_index.inter-individual | 238 |
| abstract_inverted_index.patient-specific | 249 |
| abstract_inverted_index.177Lu-[DOTA0-Tyr3] | 86, 167 |
| abstract_inverted_index.castration-resistant | 228 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 6 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8399999737739563 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.04818427 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |